PMID- 31762966
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 2040-6223 (Print)
IS  - 2040-6231 (Electronic)
IS  - 2040-6223 (Linking)
VI  - 10
DP  - 2019
TI  - The effectiveness and safety of full-dose versus half-dose corticosteroid plus 
      renin-angiotensin system blockers for IgA nephropathy.
PG  - 2040622319887875
LID - 10.1177/2040622319887875 [doi]
LID - 2040622319887875
AB  - BACKGROUND: Observational studies suggest that patients with immunoglobulin A 
      nephropathy (IgAN) showed good responses to corticosteroids (CS) but experienced 
      severe adverse effects. The authors conducted a cohort study to evaluate the 
      effectiveness and safety of half-dose CS plus renin-angiotensin system blockers 
      (RASB) (CS + RASB) versus full-dose CS in IgAN patients. METHODS: A total of 162 
      kidney biopsy-confirmed IgAN patients with protein excretion levels ⩾0.75 g/d and 
      an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) were 
      included. A total of 89 patients received half-dose CS + RASB (half CS + RASB), 
      and 73 patients received full-dose CS (full CS). The primary outcomes were the 
      complete remission rates and incidence of adverse events (AEs). The secondary 
      outcomes included 24 h urinary protein (UP) levels and a combined event. RESULTS: 
      Over the 18 months follow-up, the complete remission rates were 59% (53/89 
      patients) and 57% (42/73 patients) in the half CS + RASB and full CS groups (p = 
      0.88), respectively. A total of five patients suffered from serious AEs (SAEs) in 
      the full CS group during the observation period, and no SAEs were observed in the 
      half CS + RASB group (p = 0.012). The incidences of total AEs (p = 0.003) and 
      infections (p = 0.01) were lower in the half CS + RASB group than in the full CS 
      group. CONCLUSIONS: Although half CS + RASB versus full CS did not differ in 
      terms of reducing proteinuria, therapy with half CS + RASB resulted in fewer AEs 
      in the IgAN patients.
CI  - (c) The Author(s), 2019.
FAU - Wang, Li
AU  - Wang L
AUID- ORCID: 0000-0002-0910-0361
AD  - Department of Nephrology, The Second Affiliated Hospital of Nanchang University, 
      Donghu District, Nanchang, P.R. China.
FAU - Ren, Daijin
AU  - Ren D
AD  - Department of Nephrology, The Second Affiliated Hospital of Nanchang University, 
      Donghu District, Nanchang, P.R. China.
FAU - Huang, Tianlun
AU  - Huang T
AD  - Department of Nephrology, The Second Affiliated Hospital of Nanchang University, 
      Donghu District, Nanchang, P.R. China.
FAU - Liu, Xin
AU  - Liu X
AD  - Department of Nephrology, The Second Affiliated Hospital of Nanchang University, 
      Donghu District, Nanchang, P.R. China.
FAU - Xu, Gaosi
AU  - Xu G
AD  - Department of Nephrology, The Second Affiliated Hospital of Nanchang University, 
      No. 1, Minde Road, Donghu District, Nanchang 330006, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20191113
PL  - United States
TA  - Ther Adv Chronic Dis
JT  - Therapeutic advances in chronic disease
JID - 101532140
PMC - PMC6854762
OTO - NOTNLM
OT  - IgA nephropathy
OT  - cohort study
OT  - corticosteroids
OT  - renin-angiotensin system blockers
COIS- Conflict of interest statement: The author(s) declared no potential conflicts of 
      interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2019/11/26 06:00
MHDA- 2019/11/26 06:01
PMCR- 2019/11/13
CRDT- 2019/11/26 06:00
PHST- 2019/02/25 00:00 [received]
PHST- 2019/09/10 00:00 [accepted]
PHST- 2019/11/26 06:00 [entrez]
PHST- 2019/11/26 06:00 [pubmed]
PHST- 2019/11/26 06:01 [medline]
PHST- 2019/11/13 00:00 [pmc-release]
AID - 10.1177_2040622319887875 [pii]
AID - 10.1177/2040622319887875 [doi]
PST - epublish
SO  - Ther Adv Chronic Dis. 2019 Nov 13;10:2040622319887875. doi: 
      10.1177/2040622319887875. eCollection 2019.